Log in

NASDAQ:AIMT - Aimmune Therapeutics Stock Price, Forecast & News

$27.97
-0.33 (-1.17 %)
(As of 02/16/2020 03:05 PM ET)
Add
Today's Range
$27.55
Now: $27.97
$28.39
50-Day Range
$27.97
MA: $32.29
$36.54
52-Week Range
$16.95
Now: $27.97
$37.00
Volume1.04 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:AIMT
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees228
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.


Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics Inc (NASDAQ:AIMT) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($1.03). During the same quarter last year, the company earned ($0.89) EPS. View Aimmune Therapeutics' Earnings History.

When is Aimmune Therapeutics' next earnings date?

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Aimmune Therapeutics.

What price target have analysts set for AIMT?

11 brokerages have issued twelve-month price targets for Aimmune Therapeutics' shares. Their forecasts range from $27.00 to $81.00. On average, they expect Aimmune Therapeutics' stock price to reach $48.82 in the next year. This suggests a possible upside of 74.5% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.

What is the consensus analysts' recommendation for Aimmune Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.

What are Wall Street analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (2/5/2020)
  • 2. Stifel Nicolaus analysts commented, "We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not new" news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ worst case" scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk." (9/11/2019)

Has Aimmune Therapeutics been receiving favorable news coverage?

News articles about AIMT stock have been trending neutral this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Aimmune Therapeutics.

Are investors shorting Aimmune Therapeutics?

Aimmune Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 11,570,000 shares, an increase of 6.4% from the January 15th total of 10,870,000 shares. Based on an average trading volume of 888,400 shares, the days-to-cover ratio is currently 13.0 days. Currently, 29.0% of the shares of the company are sold short. View Aimmune Therapeutics' Current Options Chain.

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), CA (CA), Micron Technology (MU), Amarin (AMRN), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK) and Roku (ROKU).

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:
  • Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
  • Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
  • Dr. Stephen George Dilly, Special Advisor (Age 59)
  • Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Who are Aimmune Therapeutics' major shareholders?

Aimmune Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (4.59%), State Street Corp (3.51%), Victory Capital Management Inc. (3.44%), Victory Capital Management Inc. (3.41%), Fiera Capital Corp (2.66%) and Loomis Sayles & Co. L P (1.56%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright and Stephen George Dilly. View Institutional Ownership Trends for Aimmune Therapeutics.

Which institutional investors are selling Aimmune Therapeutics stock?

AIMT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Massachusetts Financial Services Co. MA, UBS Group AG, State of New Jersey Common Pension Fund D, Citigroup Inc., Rice Hall James & Associates LLC, Mackay Shields LLC and Rafferty Asset Management LLC. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman and Douglas T Sheehy. View Insider Buying and Selling for Aimmune Therapeutics.

Which institutional investors are buying Aimmune Therapeutics stock?

AIMT stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp, FMR LLC, Fiera Capital Corp, New York State Common Retirement Fund, Bank of America Corp DE and Ikarian Capital LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.

How do I buy shares of Aimmune Therapeutics?

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $27.97.


MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  436 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  731
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel